WITHUS PHARMACEUTICAL Co.,LTD.

KOSDAQ:A330350 Stock Report

Market Cap: ₩89.1b

WITHUS PHARMACEUTICALLTD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for WITHUS PHARMACEUTICALLTD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth33.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well

Nov 13
These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well

We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings

May 25
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings

Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like

Feb 17
Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like

Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)

Jan 13
Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)

We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability

Dec 09
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as WITHUS PHARMACEUTICALLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A330350 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024105,7396,725-4,8273,803N/A
6/30/202498,2747,652-10,498-1,980N/A
3/31/202490,1479,194-10,5721,252N/A
12/31/202380,1197,959-13,239-1,237N/A
9/30/202368,9753,264-12,450540N/A
6/30/202365,7941,606-17,8341,369N/A
3/31/202363,0321,057-15,5703,061N/A
12/31/202264,6802,479-12,3955,380N/A
9/30/202264,6185,424-7,1739,146N/A
6/30/202262,4615,282-4,38610,139N/A
3/31/202261,5645,089-2,8929,271N/A
12/31/202157,4194,264-2,2738,021N/A
12/31/202053,4066,652-6,414810N/A
9/30/202052,8427,075-2216,428N/A
6/30/202052,3938,0392,7927,927N/A
3/31/202053,7438,7423,9016,381N/A
6/30/201951,7328,6614,8036,765N/A
6/30/201850,9458,491N/A6,646N/A
6/30/201749,5197,332N/A8,700N/A
6/30/201645,8787,844N/A5,774N/A
6/30/201541,6407,147N/A6,441N/A
6/30/201439,1926,372N/A3,953N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A330350's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A330350's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A330350's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A330350's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A330350's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A330350's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y